Zacks Investment Research
23 Jun 2026, 14:51 UTC · 1h ago
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
23 Jun 2026, 14:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Amgen's biosimilar products generated $835 million in Q1 2026 sales, representing a 14% year-over-year increase. — Direct evidence of top-line growth and successful commercialization of new products like Wezlana and Pavblu.
+0.40Amgen faces a significant patent-expiration overhang for key branded products including Prolia, Xgeva, Enbrel, and Otezla. — Loss of exclusivity on core branded assets creates a revenue gap that the biosimilars business must fill.
-0.40Amgen is conducting Phase III studies for biosimilars targeting high-revenue biologics including Keytruda, Opdivo, and Ocrevus. — Successful entry into these massive markets represents a significant future revenue catalyst as patents expire.
+0.30Continue reading
6 related stories
Search tags
Older biosimilars such as Kanjinti, Mvasi, and Riabni are experiencing slowing or declining sales due to increased competition. — Indicates a shrinking lifecycle for early products and pricing pressure within the biosimilar segment.
-0.20Which stocks this story touches
Strong biosimilar portfolio growth and successful new product launches, despite facing future patent expirations.
Facing competitive pressure and revenue loss from Amgen's biosimilars targeting several of its key products.
Facing competition from Amgen's biosimilar Bekemv targeting Soliris.
Facing competition from Amgen's biosimilars for Remicade and Stelara.
[mutual] Amgen has launched a biosimilar of AstraZeneca's Soliris.
[mutual] Amgen produces biosimilars of J&J's Remicade and Stelara.
[mutual] Amgen produces biosimilars of Roche's Herceptin, Avastin, Rituxan, and Ocrevus.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
57m ago
